Introduction
Allergic diseases are complex phenotypes wherein the interplay between genetic factors and environmental exposures has significant influence on susceptibility and disease prognosis. Over a decade of genetic mapping and positional cloning has revealed evidence suggesting linkage to over two dozen loci for asthma alone, and association studies have identified a multitude of variants associated with traits associated with allergic disease (asthma, allergic rhinitis, atopic dermatitis). With the emergence of genomewide association studies (GWAS), the candidate gene approach is being replaced by a more unbiased approach to search for genes controlling risk to complex diseases, including atopy. In GWAS, multiple haplotype tagging single-nucleotide polymorphisms (htSNPs) from continental reference populations (i.e. the HapMap project [1]) theoretically allow detection of associations to potentially causal variants, and have successfully broadened the scope of gene discovery for many complex traits, including allergic disease. For asthma alone, nearly a dozen studies of associations using GWAS have been published, but nearly all of these have been for European ancestry populations. Of the few that have been performed in minority populations, results are inconsistent with results from GWAS performed in European-ancestry cohorts, suggesting that populations of different ethnicities, such as those of African descent, may carry unique susceptibility loci. Of concern, however, is that the efficiency of htSNPs chosen from one population (e.g. European), and originally believed to be sufficient for detection of true associations, is questionable in their representation of other continental races (e.g. African) and thereby especially important in GWAS of admixed populations (e.g. African American). This review explores the findings to date from GWAS performed in ethnically diverse populations to identify polymorphisms that confer risk to asthma and its associated 'atopy-related' traits in ethnically diverse populations. It further interrogates the pitfalls with the current GWAS technology, and considers the impact of anticipated advancements in the field, making it possible to broaden the focus of genetic studies of complex traits from populations of European ancestry to better represent minority populations.
Does genetic variation account for ethnic disparities in allergic disease?
That allergic diseases, especially asthma, are disproportionately high and continue to increase among many ethnic minorities is well accepted [2] . For example, the death rate due to asthma among African Americans is four to six times higher than among whites [3], and certain Hispanic populations (which also share African ancestry), especially Puerto Ricans, have an even higher asthma prevalence andgreater morbidity andmortality than African Americans [4] [5] [6] . For other under-represented minority groups, fewer studies have been conducted to accurately compare prevalence and morbidity, but disparities are likely. Pacific Islanders (i.e. native Hawaiians) have historically suffered from more widespread and severe asthma than other ethnic groups living in Hawaii [7] , and among 0-14-year-old children, asthma prevalence is 22% in Hawaiians/part-Hawaiians,comparedwith14%inFilipino,12%inChinese, and 8% in Japanese and whites (http://hawaii.gov/health/ statistics/hhs/hhs_07/index.html). The National Survey of Children's Health -a telephone survey in 2003-2004 of a national random sample of parents and guardians which included over 100 000 children aged 0-17 years -is one of the few large epidemiological studies to include Native Americansandcollectdataonprevalenceofallergicdisease. In this survey, disparities in prevalence of asthma and allergies were observed when comparing white, African American, Latino,Asian/Pacific Islander, Native American, and multiracial children [8] . Specifically, Native American children were more likely to be asthmatic (14.2 vs. 11.5%, P ¼ 0.0001) and have skin-related (i.e. eczema) allergies (12.0 vs. 9.2%, P ¼ 0.0001) compared with whites.
Outside of the USA, asthma prevalence is high and continues to increase in African countries and countries with African admixture (i.e. Latin America). In the most recent ISAAC report, prevalence continues to increase in the Caribbean country of Barbados specifically [9] . In the Asthma Insights and Reality in Latin America (AIRLA) survey, over 2000 adults or children in 11 Latin American countries, including Colombia and Brazil, were evaluated, and this study concludes asthma is both underdiagnosed and poorly managed [10] . What has become increasingly clear, at least among US populations, is that the striking racial and ethnic disparities in disease prevalence for common disorders, including asthma and allergies, cannot be explained entirely by environmental, social, cultural, or economic factors, and genetic factors are likely at play [11] .
A dearth of validated genetic determinants for asthma and allergic disease among ethnic minorities Asthma and its associated trait 'atopy' were perhaps some of the first complex diseases for which a strong genetic basis was established [12] [13] [14] . Nearly a dozen genomewide linkage screens have been performed on asthma and its associated phenotypes [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] , which have identified 10 chromosomal regions giving multiple reports of linkage. From several of these family-based genomewide linkage screens, six novel genes were identified by further positional cloning [25] [26] [27] [28] [29] [30] .
The huge research efforts and expense committed to asthma genetics from candidate gene and linkage studies have changed the perception about the cause of asthma and allergic disease, including a new appreciation for the role of innate as well as adaptive immune-response genes, and the potential importance of the epithelial barrier and its defense mechanisms in asthma [14, 31] . However, genomewide approaches have the advantage of being completely unbiased from a genetic perspective, and have emerged as a powerful approach for detecting novel genetic variants with plausible effect sizes for a plethora of complex traits, including asthma. To date, nearly 600 GWAS have been published on a plethora of complex traits [32 ] .
Notably, however, the GWAS performed so far have focused primarily on European ancestry populations as the discovery population, with very limited replication in non-European groups. In a review of 570 references from 'A Catalog of Published Genome-Wide Association Studies' (http://www.genome.gov/gwastudies/), as of March 2010, there have only been 72 studies that included cohorts from non-European populations (Fig. 1, panel a) . Within the asthma community, 13 groups have published results from their GWAS on asthma; however, of the asthma GWAS completed to date, only one focused on African Americans [33 ] and two focused on Hispanics [34 ,35] (Fig. 1, panel b ). To date, one GWAS has been published on AD (atopic dermatitis) in a German sample [36 ] , replicated in an independent German group, and a second, European-based GWAS is in the replication phase. A GWAS focusing on total IgE as the primary outcome [37] leveraged the GABRIEL consortium (http://www.gabriel-fp6.org/public/index.htm), the European sample selected for asthma (currently 10 000 asthma cases and 16 000 nonasthmatic controls) from which the first results from a GWAS for asthma were generated.
The initial GABRIEL report demonstrated strong association between asthma and markers near the ORMDL3 gene on chromosome 17q21 (P < 10 À12 ) [38] , and has been widely replicated in several European ancestry [39] [40] [41] [42] [43] , Asian [44, 45] and Hispanic [46, 47] populations. However, the SNPs significantly associated in the discovery population were not associated in nearly 3500 African Americans from Philadelphia [48] , an African American sample from San Francisco/Oakland area [46] , or African American and African Caribbean populations from Baltimore/Washington, DC and Barbados, respectively [33 ] . The San Francisco group did report significant association between a different ORMD3 SNP (rs9894164) and asthma among African Americans, but this marker was not on the original commercial SNP chip, underscoring the challenges in replicating SNP-for-SNP findings from GWAS performed in European populations. In the first asthma GWAS focusing exclusively on populations of African descent, replication at a SNP-for-SNP level was not observed across multiple independent populations; however, three genes (CTNNA3, DPP10 and KCNMA1) that showed evidence for association in the African-ancestry discovery samples were replicated in a European population using a gene-based approach [33 ] . Conclusions drawn from this study include the possibility that subtle differences in ancestry between populations can lead to a failure to replicate associations for individual SNPs, even when gene-based evidence does exist.
In one of the few observations of SNP-for-SNP replication of a GWAS for asthma, Sleiman et al. [49 ] observed significant associations between variants in the gene encoding DENND1B in a large sample of European Americans (P ¼ 7.8 Â 10 À8 ), which replicated in independent European-ancestry samples. Replication was also found in a combined African American case-control group, but the association was with a different allele and the estimated odds ratio (OR) was in the opposite direction. This 'flip-flop' phenomenon across different ethnic groups may reflect differences in genetic background and/or differences in linkage disequilibrium across populations, especially when noncausal 'tag' markers are tested [50] (as is typical in GWAS using commercial chips). These observations similarly underscore the complexities of drawing firm conclusions from marker panels in distinct subpopulations, and the need to test beyond simple SNP-for-SNP replication.
The complexities of ethnically admixed populations in genetic association studies
Genetic structure and substructure occurs when a population comprises more than one or more ethnic/racial groups representing different ancestries. Ethnic or racial admixture is particularly relevant for genetic studies in the USA and elsewhere in the Americas, where the unique population history has been characterized by a mixture of European ancestry with West Africans, indigenous groups (northern and southern Native Americans, as in the case of Mestizos in Central and South America), and a multitude of people from other distinct geographical regions. A serious problem arises when the disease of interest (e.g. asthma, atopy) is more prevalent in a particular group (or groups) within the population, because any alleles that are more common among the minority group(s) of interest will tend to be associated with the disease, even if completely unlinked to the disease-causing locus. This phenomenon is referred to as 'population stratification', and the consequent confounding due to population stratification can lead to spurious associations between genetic markers, especially in population-based (i.e. case-control) studies, and can limit generalizability of results to the broader population [51] [52] [53] .
Whereas matching the self-reported ethnic backgrounds of cases and controls in study design is one possibility, it is still possible to have hidden, or 'cryptic' stratification [54] . GWAS has accelerated the development of statistical approaches toward detecting stratification and Genomewide association studies in allergy Barnes 429 controlling for ancestral differences in association testing. Currently there are a variety of algorithms that employ nonhierarchical cluster analysis or principal component analysis (PCA) for these statistical approaches [55, 56] . Correction for population stratification is typically performed using information on either markers for which allele frequencies differ substantially between ancestral populations referred to as 'ancestry informative markers' (AIMs); or leveraging the large number of markers available in GWAS studies in which it is easy to argue most are in fact unlinked to the true susceptibility loci for the disease under consideration [55, [57] [58] [59] [60] [61] .
African Americans represent a racial/ethnic group that is both disproportionately affected by asthma and allergic disease (as described above) and a classic admixed population. To this end, ancestry estimation in this group has been extensively pursued. Relatively early studies demonstrated that African Americans comprise approximately 18-20% European ancestry, but within the USA this proportion can vary regionally [62] . African Caribbean populations are believed to be similar in terms of genetic ancestry, but using a relatively modest panel of AIMs, Benn-Torres et al. [63] estimated the West African component to be higher (up to 90%) among certain West Indian groups.
In the first GWAS focused on populations of African descent, 417 AIMs were used combined with similar genotypic data from 240 unrelated individuals drawn from the HAPMAP data resource (60 YRI, 60 CEU, and 120 CHB/JPT) to define 'ancestral populations' while estimating admixture in the approximately 2000 study samples. Cases and controls were shown to be highly admixed with a balanced estimated proportion of African genes of 72.2 and 72.4%, respectively [33 ] . It was further demonstrated that, after expanding this analysis to a large subset ($14 000 SNPs) of the full panel of autosomal SNPs from the GWAS chip (>620K) and also including two East African (Maasai and Luhya) populations from the newest version of HapMap, phase III, the AIMs were just as good for detecting substructure larger numbers of random markers [64 ] . These approaches for a variety of populations expected to have prominent African admixture component, as illustrated in Fig. 2 , show the highest proportion of YRI ancestry in the African Americans, Barbadians and Jamaicans (73-88%), and lower proportions in the Brazilian and Colombian data (38-50%).
Admixture and the impact of population stratification are not limited to overtly admixed populations, as demonstrated by Tian et al. [65] , who demonstrated a spurious correlation between SNPs in strong linkage disequilibrium with a candidate gene for rheumatoid arthritis in a set of rheumatoid arthritis cases recruited from multiple US sites compared with a group of selfidentified European Americans recruited in New York City. In this study, the investigators used a set of putative European substructure AIMs (ESAIMs), and demonstrated that the large differences in allele frequency for a gene initially showing a strong association with RA was actually due to the difference in allele frequency among different European subpopulation groups, whereby the largest allele frequency difference was between predominantly Irish controls from New York City and cases of Northern, Central, and Eastern European descent. These studies together underscore the importance of considering population stratification in any population-based genetic association study, perhaps most importantly in populations with a known strong admixture component.
Technological limitations: coverage on commercially available genomewide association studies chips and power for genomewide association studies
The GWAS approach is predicated on the notion that data cataloged in the International HapMap Project, combined with more accurate approaches in selecting tagging markers, will be sufficiently dense to capture most of the common variation in the human genome. As described elsewhere, HapMap was initially generated from 269 DNA samples representing four biogeographical groups. This has recently been expanded to 1115 individuals from 11 populations [66] . However, the commercial enterprises that create the chips have, for the most part, relied upon the European ancestry reference panel as a proxy for all continental groups. Not surprisingly, the GWAS approach is most successful in situations in which the genetic variants evaluated are selected from populations most representative of the study population at hand (i.e. European Americans genotyped on markers largely selected from the CEU Hap-Map sample). Next-generation sequencing technologies are rapidly driving the costs of assessing variation at every site in the genome down at a somewhat constant rate, and these may eventually replace commercially available genomewide platforms and at the very least compete with the price of capturing just a fraction of variable sites (e.g. via high-density SNP arrays). Nevertheless, currently, the cost of a whole genome sequence is still prohibitive, so using SNP arrays will, for the immediate future, continue to be the most cost-effective strategy for GWAS.
A recently published perspective on the scientific value of GWAS [67 ] suggested currently available commercial chips do capture the bulk of common genetic variation, and SNPs with large effects may have already been discovered, implying there is no need for additional genomewide scans, and focus should therefore shift towards a detailed search for rare variants. However, it is difficult to argue most important SNPs have already been discovered, if what constitutes one of the largest and most genetically heterogeneous continental populations -Africans -is so severely under-represented in the GWAS literature. Second, whereas the collective findings of GWAS do support the notion that most identified genetic risk factors only account for a small fraction of observed heritability of most complex diseases and typically have an effect size less than 1.5, it is probable that multiple rare causal variants are more likely to be found in African ancestry populations and further argues for greater focus on this ethnic group.
In a recent analysis by co-investigator Bhangale et al. [66] , 76 genes were resequenced in unrelated HapMap samples (24 YRI, 23 CEU) and they examined coverage of all genetic variation data using various commercial genotyping arrays and phase II HapMap SNPs to capture common variants in these 76 genes. In direct comparisons of coverage performance of the commercial arrays compared with the Seattle SNP-based coverage at r 2 at least 0.8, the commercial chip with the highest proportion of YRI SNPs only provided an estimated 55% coverage.
The limitations of the current technology are especially apparent in data that are emerging from the '1000 Genomes' project (http://www.1000genomes.org), an international research consortium which aims to create the most detailed catalog to date of human genetic variation and provide a resource that will be useful for human disease studies. Samples from about 2000 indi-Genomewide association studies in allergy Barnes 431 viduals from approximately 22 populations are being sequenced with the goal of finding nearly all DNA sequence variants. Relying on phase I data, which includes the greatly expanded whole genome sequencing of the original four continental populations represented in HapMap, more than 17 million SNPs from 181 samples have been identified, which includes more than 9M novel-discovery SNPs. In other words, approximately 54% SNPs were not previously reported in the public database (Mathias, Qin, Abecasis, unpublished data). As illustrated in Fig. 3 , in the YRI data specifically, there are 12 068 821 SNPs identified in 50 samples, of which 5 953 505 were novel SNPs. Moreover, in an assessment of the overlap in variation between the four HAPMAP populations, each population has a set of unique SNPs (0.51-5.65 million), with the largest representation of unique variation in the YRI samples, with 5.65 million unique SNPs.
Conclusion
Despite the major advancements in the identification of novel genes associated with asthma and allergic disease through GWAS, few studies have been conducted in non-European populations. GWAS in ethnically and racially diverse populations demands consideration of characteristics unique to underrepresented cohorts, including population heterogeneity due to admixture. A critical limitation in conducting GWAS on ethnically and racially diverse samples arises because commercially available chips were constructed using SNPs identified in European-derived samples and the density of these SNP panels does not provide adequate coverage. New technologies are on the horizon that promise to more accurately capture the genetic diversity of all continental populations, and advance the field.
